Business Challenges in Commercialization of Agricultural Technology

Technology has been a major driver of both the agricultural productivity increases of the past century and the financial success of many farm and agribusiness firms. The challenges of bringing new technology to market in the agricultural industry are changing - it is no longer adequate to conceive a new invention and convince farmers with a strong marketing campaign that they should adopt the technology that results from this invention. One of the plenary sessions at the 2003 IAMA meetings in Cancun focused on the challenges and opportunities in creating value from new technology. Participants included: Michael Boehlje, Center for Food and Agricultural Business, Purdue University; Lynn White, Vice President, Global Ag Services, Deere; Marcello Arguelles, CEO of Biosidus; and Greg Clarke, Technical Director, FXA Group. This synopsis attempts to capture the key observations of the session presenters and the discussion that followed.Research and Development/Tech Change/Emerging Technologies,

Nanogels for pharmaceutical and biomedical applications and their fabrication using 3D printing technologies

Nanogels are hydrogels formed by connecting nanoscopic micelles dispersed in an aqueous medium, which give an opportunity for incorporating hydrophilic payloads to the exterior of the micellar networks and hydrophobic payloads in the core of the micelles. Biomedical and pharmaceutical applications of nanogels have been explored for tissue regeneration, wound healing, surgical device, implantation, and peroral, rectal, vaginal, ocular, and transdermal drug delivery. Although it is still in the early stages of development, due to the increasing demands of precise nanogel production to be utilized for personalized medicine, biomedical applications, and specialized drug delivery, 3D printing has been explored in the past few years and is believed to be one of the most precise, efficient, inexpensive, customizable, and convenient manufacturing techniques for nanogel production

Recent Trends, Opportunities and Challenges in 3D Printing Technology for Personalize Medicine

The scrutiny of medical devices industry as well as pharmaceutical industry for its application in health care industry on different platform is captured the 3D printing technique.  3D printing technology withstand for a very long duration only because of the approval of medical devices, 3D printed tablets and also with the advent of USFDA guideline on technical consideration. This technology is specific to devices utilizing preservative manufacturing. Many thoughts are triggered by 3D printing this technology and for successful delivery of intended product which is necessarily take into a consideration. In this review paper expectation limitations of some regulatory companies, Advantages, disadvantages, what type problems are arises while establishing this setups for drug product production, method, application, and manufacturing risk are represented. It also gives information about the current status of 3D printing technology in research and development of drug products.  For the fabrication of novel solid dosage form a number of 3D printing technology have been developed. This review is mainly focused on describing different technology used for the application of 3D printing in pharmaceutical industry.  Keywords: - 3D printing technology, recent trend, Opportunities, personalize medicine, challenges, future

Future Agribusiness Challenges: Strategic Uncertainty, Innovation and Structural Change

The IFAMR is published by the International Food and Agribusiness Management Association.(IFAMA) www.ifama.orgStrategic uncertainty, innovation, structural change, Agribusiness, Research and Development/Tech Change/Emerging Technologies, Risk and Uncertainty, ISSN #: 1559-2448,

Smart process manufacturing for formulated products

We outline the smart manufacturing challenges for formulated products, which are typically multicomponent, structured, and multiphase. These challenges predominate in the food, pharmaceuticals, agricultural and specialty chemicals, energy storage and energetic materials, and consumer goods industries, and are driven by fast-changing customer demand and, in some cases, a tight regulatory framework. This paper discusses progress in smart manufacturing—namely, digitalization and the use of large datasets with predictive models and solution-finding algorithms—in these industries. While some progress has been achieved, there is a strong need for more demonstration of model-based tools on realistic problems in order to demonstrate their benefits and highlight any systemic weaknesses

The Price of Progress: Funding and Financing Alzheimer\u27s Disease Drug Development

Introduction Advancing research and treatment for Alzheimer\u27s disease (AD) and the search for effective treatments depend on a complex financial ecosystem involving federal, state, industry, advocacy, venture capital, and philanthropy funding approaches. Methods We conducted an expert review of the literature pertaining to funding and financing of translational research and drug development for AD. Results The federal government is the largest public funder of research in AD. The National Institute on Aging, National Institute of Mental Health, National Institute of General Medical Sciences, and National Center for Advancing Translational Science all fund aspects of research in AD drug development. Non-National Institutes of Health federal funding comes from the National Science Foundation, Veterans Administration, Food and Drug Administration, and the Center for Medicare and Medicaid Services. Academic Medical Centers host much of the federally funded basic science research and are increasingly involved in drug development. Funding of the “Valley of Death” involves philanthropy and federal funding through small business programs and private equity from seed capital, angel investors, and venture capital companies. Advocacy groups fund both basic science and clinical trials. The Alzheimer Association is the advocacy organization with the largest research support portfolio relevant to AD drug development. Pharmaceutical companies are the largest supporters of biomedical research worldwide; companies are most interested in late stage de-risked drugs. Drugs progressing into phase II and III are candidates for pharmaceutical industry support through licensing, mergers and acquisitions, and co-development collaborations. Discussion Together, the funding and financing entities involved in supporting AD drug development comprise a complex, interactive, dynamic financial ecosystem. Funding source interaction is largely unstructured and available funding is insufficient to meet all demands for new therapies. Novel approaches to funding such as mega-funds have been proposed and more integration of component parts would assist in accelerating drug development

Human resource management and learning for innovation: pharmaceuticals in Mexico

This paper investigates the influence of human resource management on learning from internal and external sources of knowledge. Learning for innovation is a key ingredient of catching-up processes. The analysis builds on survey data about pharmaceutical firms in Mexico. Results show that the influence of human resource management is contingent on the knowledge flows and innovation goals pursued by the firm. Practices such as training-- particularly from external partners; and remuneration for performance are conducive to learning for innovation.Learning, R&D, human resource management, pharmaceuticals, Mexico